Time to first treatment and P53 dysfunction in chronic lymphocytic leukaemia: results of the O-CLL1 study in early stage patients

Chronic lymphocytic leukaemia (CLL) is characterised by a heterogeneous clinical course. Such heterogeneity is associated with a number of markers, including TP53 gene inactivation. While TP53 gene alterations determine resistance to chemotherapy, it is not clear whether they can influence early dis...

Descripción completa

Detalles Bibliográficos
Autores principales: Monti, Paola, Lionetti, Marta, De Luca, Giuseppa, Menichini, Paola, Recchia, Anna Grazia, Matis, Serena, Colombo, Monica, Fabris, Sonia, Speciale, Andrea, Barbieri, Marzia, Gentile, Massimo, Zupo, Simonetta, Dono, Mariella, Ibatici, Adalberto, Neri, Antonino, Ferrarini, Manlio, Fais, Franco, Fronza, Gilberto, Cutrona, Giovanna, Morabito, Fortunato
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7595214/
https://www.ncbi.nlm.nih.gov/pubmed/33116240
http://dx.doi.org/10.1038/s41598-020-75364-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7595214/
https://www.ncbi.nlm.nih.gov/pubmed/33116240
http://dx.doi.org/10.1038/s41598-020-75364-3

Ejemplares similares